Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GAUTAM BORTHAKUR

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1629177944
CMS profile
346312
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,357.33

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,280.00 2
Food and Beverage $77.33 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $2,679.99 2
Takeda Pharmaceuticals U.S.A., Inc. $677.34 2

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GAUTAM BORTHAKUR

NPI 1629177944 · CMS profile ID 346312

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GAUTAM BORTHAKUR, NPI 1629177944, CMS profile ID 346312, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1629177944?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $3,357.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $2,620.0012/06/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658935717 CMS
Novartis Pharmaceuticals Corporation $59.9912/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658935723 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.3409/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697401041 CMS
Takeda Pharmaceuticals U.S.A., Inc. $660.0006/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697373893 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,357.33 4
PY2021 $272.24 2
PY2022 $3,052.27 7
PY2023 $3,419.07 6
PY2024 $112.20 2
PY2025 $151.62 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $481,974.58 1
PY2024 Principal investigator $79,669.55 3
PY2023 Recipient $71,592.50 1
PY2023 Principal investigator $36,848.00 3
PY2022 Principal investigator $569,901.54 33
PY2021 Principal investigator $404,764.38 36
PY2020 Recipient $1,087.58 1
PY2020 Principal investigator $558,754.27 55
PY2019 Recipient $103.92 2
PY2019 Principal investigator $1,118,089.03 60

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $4,121.00 12/20/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603869
Principal investigator 1 Janssen Research & Development, LLC $1,704.00 12/03/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603859
Principal investigator 1 Janssen Research & Development, LLC $8,656.00 11/01/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603825
Principal investigator 1 Janssen Research & Development, LLC $14,248.60 10/15/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed Refractory Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 787604189
Principal investigator 1 Janssen Research & Development, LLC $3,771.00 10/04/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603801
Principal investigator 1 GlaxoSmithKline, LLC. $7,556.85 09/29/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 3
A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF No dispute reported 06/30/2026 860870737
Principal investigator 1 Janssen Research & Development, LLC $6,851.50 08/27/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603719
Principal investigator 1 Otsuka Pharmaceutical Co., Ltd. $29,047.07 08/19/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
A PHASE 1, PARALLEL, OPEN-LABEL STUDY OF THE SAFETY AND TOLERABILITY, PHARMACOKINETICS, AND ANTILEUKEMIC ACTIVITY OF ASTX660 AS A SINGLE AGENT AND IN COMBINATION WITH ASTX727 IN SUBJECTS WITH RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) No dispute reported 06/30/2026 765251864
Principal investigator 1 Janssen Research & Development, LLC $9,543.50 08/05/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603727
Principal investigator 1 AstraZeneca UK Limited $94,392.15 07/28/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
A Phase I/II Open-Label Multicentre 2-Part Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-Na?ve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy No dispute reported 06/30/2026 826474865
Principal investigator 1 Janssen Research & Development, LLC $727.00 06/28/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603661
Principal investigator 1 Janssen Research & Development, LLC $11,090.50 06/28/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603669
Principal investigator 1 GlaxoSmithKline, LLC. $3,035.00 05/31/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF No dispute reported 06/30/2026 809497063
Principal investigator 1 Janssen Research & Development, LLC $3,769.00 05/24/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open label Multi Center Phase 1b Study of JNJ74494550 Cusatuzumab; AntiCD70 Monoclonal Antibody in Combination with Background Therapy for the Treatment of Subjects with Acute Myeloid Leukemia No dispute reported 06/30/2026 787603619
Principal investigator 1 Janssen Research & Development, LLC $17,538.70 05/03/2021 Covered Recipient Teaching Hospital
Ut Md Anderson Cancer Center
An Open Label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed Refractory Acute Myelogenous Leukemia and High Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 787604172
Principal investigator 1 PTC Therapeutics, Inc. $51,810.00 05/01/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS No dispute reported 06/30/2026 849320363
Principal investigator 1 PTC Therapeutics, Inc. $51,810.00 05/01/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS No dispute reported 06/30/2026 849320367
Principal investigator 1 GlaxoSmithKline, LLC. $50.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809478581
Principal investigator 1 GlaxoSmithKline, LLC. $18,750.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809478711
Principal investigator 1 GlaxoSmithKline, LLC. $5,901.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809479531
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809479533
Principal investigator 1 GlaxoSmithKline, LLC. $1,875.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809479535
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809479561
Principal investigator 1 GlaxoSmithKline, LLC. $1,125.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809479563
Principal investigator 1 GlaxoSmithKline, LLC. $2,254.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809481783
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809481785
Principal investigator 1 GlaxoSmithKline, LLC. $10,000.00 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809481787
Principal investigator 1 GlaxoSmithKline, LLC. $2,971.55 03/23/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809481789
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 03/10/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809478607
Principal investigator 1 GlaxoSmithKline, LLC. $2,191.00 03/10/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809478709
Principal investigator 1 GlaxoSmithKline, LLC. $5,000.00 03/10/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809478713
Principal investigator 1 GlaxoSmithKline, LLC. $2,430.00 03/10/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809479529
Principal investigator 1 GlaxoSmithKline, LLC. $2,160.00 03/10/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809481781
Principal investigator 1 GlaxoSmithKline, LLC. $8,000.00 03/10/2021 Non-covered Recipient Entity
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
A PHASE I/II OPEN-LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFE No dispute reported 06/30/2026 809481817
Principal investigator 1 PTC Therapeutics, Inc. $3,271.00 03/01/2021 Covered Recipient Teaching Hospital
UT MD ANDERSON CANCER CENTER
PHASE 1B STUDY OF PTC299 IN RELAPSED/REFRACTORY ACUTE LEUKEMIAS No dispute reported 06/30/2026 849320359
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,813.96 01/18/2021 Non-covered Recipient Entity
UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
ELTROMBOPAG FOR THE MANAGEMENT OF THROMBOCYTOPENIA ASSOCIATED WITH TYROSINE KINASE THERAPY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA CML No dispute reported 06/30/2026 800647629